SGX queries Biolidics on A*Star licence deal
Add BT as a preferred sourceClaudia Tan HS
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
THE Singapore Exchange (SGX) on Wednesday posed a series of queries to Biolidics about the details of a licence agreement the Catalist-listed firm had inked as well as the timing of its trading halt and announcement.
In a filing late Tuesday night, Biolidics said it had on July 9 entered into a five-year licence agreement with Accelerate Technologies, the commercialisation arm of the Agency for Science, Technology and Research (A*Star), to use the agency's technology for the detection of Covid-19 viral spike/Angiotensin-Converting Enzyme 2 (ACE2) blocking antibodies.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Singaporeans can now buy record amount of yen per Singdollar
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
StarHub hands Ensign InfoSecurity control back to Temasek in S$115 million deal, books S$200 million gain
